Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javle

Showing results (321-330 of 343) with videos related to

Pageof 35
Sort By:
Nature Communications|October 22, 2020
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancersSherille D Bradley, Amjad H Talukder, Ivy Lai, et al.
International Journal of Radiation Oncology, Biology, Physics|July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker ValidationEugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Physical Biology|November 27, 2014
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancerEugene J Koay, Flavio E Baio, Alexander Ondari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
Cancer Cell|April 3, 2018
Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic CancerYing-Nai Wang, Heng-Huan Lee, Chao-Kai Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaMilind Javle, Maeve Lowery, Rachna T Shroff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2026
Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative RadiotherapyJoseph Abi Jaoude, Alexandria Lau, Yinyin Yuan, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
Pageof 35

Showing results (321-330 of 343) with videos related to

Sort By:
Pageof 35
Nature Communications|October 22, 2020
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancersSherille D Bradley, Amjad H Talukder, Ivy Lai, et al.
International Journal of Radiation Oncology, Biology, Physics|July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker ValidationEugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Physical Biology|November 27, 2014
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancerEugene J Koay, Flavio E Baio, Alexander Ondari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
Cancer Cell|April 3, 2018
Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic CancerYing-Nai Wang, Heng-Huan Lee, Chao-Kai Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaMilind Javle, Maeve Lowery, Rachna T Shroff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2026
Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative RadiotherapyJoseph Abi Jaoude, Alexandria Lau, Yinyin Yuan, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
Pageof 35